Alirocumab cuts cardiac mortality in patients with diabetes
Findings provide 'greater reassurance' of glycaemic safety of PCSK9 inhibitors, study authors say
4th July 2019
By Kemal Atlay
The PCSK9 inhibitor alirocumab conveys almost double the cardio-protective benefit in patients with diabetes following acute coronary syndrome than those without diabetes, a large international trial has shown.
The study, funded by Sanofi and Regeneron Pharmaceuticals, also suggests that an aggressive lipid-lowering treatment with an LDL cholesterol concentration target of 0.65-1.30mmol/L does not increase the risk of new-onset diabetes, the researchers say.
In the multicentre ODYSSEY OUTCOMES study, 18,900 patients (aged 50-66) hospitalised with ACS 1-12
